CClinicalTrials.gg
CompletedNCT07662577Updated Jun 23, 2026

Controlled Hypotension and Renal Injury During Septoplasty

An interventional study of Controlled Hypotension (MAP 50-57 mmHg) and Controlled Hypotension (MAP 58-65 mmHg) in Hypotension During Surgery, NGAL and Kidney Injury, sponsored by Fatih Sultan Mehmet Training and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Fatih Sultan Mehmet Training and Research Hospital · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 7 years 1 month after the study started (first participant enrolled May 2019, registered Jun 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This prospective randomized single-blind study investigated the effects of two different mean arterial pressure (MAP) targets during controlled hypotension on renal injury in patients undergoing septoplasty. Participants were randomized to a low MAP target group (50-57 mmHg) or a higher MAP target group (58-65 mmHg). Renal injury was assessed using plasma neutrophil gelatinase-associated lipocalin (NGAL) levels measured at baseline, 6 hours, and 24 hours postoperatively.

Read the detailed description

Controlled hypotension is frequently used during septoplasty to reduce intraoperative bleeding and improve surgical field visibility. However, excessive reductions in mean arterial pressure (MAP) may impair renal perfusion and potentially contribute to postoperative kidney injury. Traditional markers of renal dysfunction, such as serum creatinine, may not detect early renal injury. Neutrophil gelatinase-associated lipocalin (NGAL) has emerged as a sensitive biomarker for the early detection of acute kidney injury.

This prospective randomized study was designed to evaluate the effects of two different MAP target ranges during controlled hypotension on renal injury in patients undergoing elective septoplasty under general anesthesia. Patients were randomly assigned to one of two groups: a lower MAP target group (50-57 mmHg) and a higher MAP target group (58-65 mmHg). Controlled hypotension was achieved according to standard anesthetic practice throughout surgery.

Renal injury was assessed by measuring plasma NGAL concentrations preoperatively and at predetermined postoperative time points. Additional renal function parameters, including serum creatinine levels, urine output, and acute kidney injury classifications, were evaluated. Intraoperative hemodynamic variables and renal regional oxygen saturation values were also recorded.

The primary objective of the study was to determine whether different levels of controlled hypotension influence early renal injury as assessed by NGAL measurements. Secondary objectives included evaluation of conventional renal function parameters, renal tissue oxygenation, and perioperative hemodynamic outcomes.

02

Conditions studied

  • Hypotension During Surgery
  • NGAL
  • Kidney Injury

Browse trials for

Keywords

  • NGAL
  • Kidney Injury
  • Hypotension
  • NIRS
03

In context

Hypotension

1,003 studies on the registry are indexed under Hypotension; 173 are open to participants now.

This study's enrollment of 110 is above the median of 80 across 675 interventional studies indexed under Hypotension.

Browse Hypotension studies →

Lead sponsor

Fatih Sultan Mehmet Training and Research Hospital is the lead sponsor of 118 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adults aged 18 to 65 years
  • Scheduled for elective septoplasty under general anesthesia
  • American Society of Anesthesiologists (ASA) physical status I-II
  • Planned controlled hypotension during surgery
  • Provided written informed consent

Exclusion criteria

Exclusion Criteria:

  • Body mass index (BMI) > 35 kg/m²
  • History of hypertension
  • Diabetes mellitus
  • Coronary artery disease
  • Cerebrovascular disease
  • Carotid artery stenosis
  • Vertebrobasilar insufficiency
  • Pre-existing renal dysfunction
  • Anemia
  • Hypovolemia
  • Refusal to participate in the study
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    Low MAP Group

    Participants underwent controlled hypotension during septoplasty with a target mean arterial blood (MAP) range 50-57mmHg.

    Procedure: Controlled Hypotension (MAP 50-57 mmHg)

  • Experimental
    High MAP Group

    Participants underwent controlled hypotension during septoplasty with a target MAP range of 58-65 mmHg according to the study protocol.

    Procedure: Controlled Hypotension (MAP 58-65 mmHg)

Interventions

  • ProcedureControlled Hypotension (MAP 50-57 mmHg)

    Controlled hypotension was maintained intraoperatively with a target MAP range of 50-57 mmHg according to the study protocol.

  • ProcedureControlled Hypotension (MAP 58-65 mmHg)

    Controlled hypotension was maintained intraoperatively with a target MAP range of 58-65 mmHg according to the study protocol.

06

What researchers measure

Primary outcomes

  1. Plasma Neutrophil Gelatinase-Associated Lipocalin (NGAL) concentration

    Plasma NGAL concentrations were measured to assess early renal injury associated with different target mean arterial pressure ranges during controlled hypotension.

    Time frame: After anesthesia induction as a baseline, 6 hours and 24 hours post-induction

Secondary outcomes

  1. Serum Creatinine Concentration

    Serum Creatinine levels were measured to evaluate postoperatinve renal function.

    Time frame: After anesthesia induction as a baseline, 6 hours and 24 hours post-induction

  2. Acute Kidney Injury Network (AKIN) Classification

    AKIN scores were determined using serum creatinine measurements and calculated urine output values obtained during the first 24 postoperative hours.

    Time frame: After anesthesia induction 6,12 and 24th hours

  3. Urine Output

    Urine volumes were collected in separate containers during the first 6 hours, the second 6 hours, and the subsequent 12 hours following anesthesia induction. Hourly urine output per kilogram body weight was calculated for the 0-6, 0-12, and 0-24 hour periods.

    Time frame: 0-6 hours, 6-12 hours, and 12-24 hours after anesthesia induction

  4. Renal Regional Oxygen Saturation (rSO₂)

    Renal regional oxygen saturation (rSO₂) was measured using near-infrared spectroscopy (NIRS) to evaluate the effects of different controlled hypotension targets on renal tissue oxygenation during septoplasty.

    Time frame: Throughout surgery and at predefined intraoperative measurement time points

07

Study locations

1 site
  • FSMTRH
    Istanbul, Ataşehir 34752, Turkey (Türkiye)
08

References and documents

Publications

  • Khanna AK, Maheshwari K, Mao G, Liu L, Perez-Protto SE, Chodavarapu P, Schacham YN, Sessler DI. Association Between Mean Arterial Pressure and Acute Kidney Injury and a Composite of Myocardial Injury and Mortality in Postoperative Critically Ill Patients: A Retrospective Cohort Analysis. Crit Care Med. 2019 Jul;47(7):910-917. doi: 10.1097/CCM.0000000000003763. PubMed 30985388 ↗
  • Hoste EA, Kellum JA. RIFLE criteria provide robust assessment of kidney dysfunction and correlate with hospital mortality. Crit Care Med. 2006 Jul;34(7):2016-7. doi: 10.1097/01.CCM.0000219374.43963.B5. No abstract available. PubMed 16801870 ↗
  • Murkin JM, Arango M. Near-infrared spectroscopy as an index of brain and tissue oxygenation. Br J Anaesth. 2009 Dec;103 Suppl 1:i3-13. doi: 10.1093/bja/aep299. PubMed 20007987 ↗
  • Soni SS, Cruz D, Bobek I, Chionh CY, Nalesso F, Lentini P, de Cal M, Corradi V, Virzi G, Ronco C. NGAL: a biomarker of acute kidney injury and other systemic conditions. Int Urol Nephrol. 2010 Mar;42(1):141-50. doi: 10.1007/s11255-009-9608-z. Epub 2009 Jul 7. PubMed 19582588 ↗
  • Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A; NGAL Meta-analysis Investigator Group. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009 Dec;54(6):1012-24. doi: 10.1053/j.ajkd.2009.07.020. Epub 2009 Oct 21. PubMed 19850388 ↗
  • Haase M, Devarajan P, Haase-Fielitz A, Bellomo R, Cruz DN, Wagener G, Krawczeski CD, Koyner JL, Murray P, Zappitelli M, Goldstein SL, Makris K, Ronco C, Martensson J, Martling CR, Venge P, Siew E, Ware LB, Ikizler TA, Mertens PR. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J Am Coll Cardiol. 2011 Apr 26;57(17):1752-61. doi: 10.1016/j.jacc.2010.11.051. PubMed 21511111 ↗
  • Salmasi V, Maheshwari K, Yang D, Mascha EJ, Singh A, Sessler DI, Kurz A. Relationship between Intraoperative Hypotension, Defined by Either Reduction from Baseline or Absolute Thresholds, and Acute Kidney and Myocardial Injury after Noncardiac Surgery: A Retrospective Cohort Analysis. Anesthesiology. 2017 Jan;126(1):47-65. doi: 10.1097/ALN.0000000000001432. PubMed 27792044 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07662577
Lead sponsor
Fatih Sultan Mehmet Training and Research Hospital
Responsible party
Gamze Nur Teke (medical doctor, Fatih Sultan Mehmet Training and Research Hospital) — Principal investigator
First posted
Jun 23, 2026
Start date
May 1, 2019
Primary completion
May 1, 2020
Completion
Aug 1, 2020
Last update
Jun 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion